CAMBRIDGE, MA, September 26, 2017-- Aurora BioPharma, Inc. announces its CEO, Robert Brooks, will attend the 17th Annual Biotech in Europe Forum for Global Partnering & Investment taking place September 26th - 27th, 2017 at the Congress Center Basel in Basel, Switzerland for partnering sessions.
The event will be held for the fourth time in Basel to be close to the largest biopharma hub in Europe. The high profile forum is recognized as a leading international stage for those interested in investing and partnering with biopharmaceutical and biotechnology companies. The conference attracts a cross-section of early-stage/pre-IPO, late-stage and public companies, leading investors, analysts, and money managers who participate in forum events featuring eminent speakers.
Aurora is leading in the development of Chimeric Antigen Receptor (CAR) T therapy in solid tumors, with a diversified mid-stage clinical pipeline. Aurora's CAR T drug AU105 completed Phase I/IIa clinical trial in 16 Glioblastoma patients showing safety, tumor killing efficacy, double the median historic overall survival, with 3 patients alive after 5 years. Aurora's CAR T drug AU101 completed a Phase IIa trial in 6 Sarcoma patients, showing safety, tumor-killing and a Complete Response -- cancer free after 5 years. Aurora is planning a pivotal trial of its CAR T Cell therapy in Glioblastoma and Osteosarcoma.
This press release and any statements of representatives and partners of Aurora BioPharma, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company's control. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Aurora BioPharma, Inc.
Tel: (617) 674-7718
Fax: (617) 674-7701
SOURCE Aurora BioPharma, Inc.